🔗 Share this article

Given that the United States undertakes historic revisions to its immunization recommendations, a particular individual appears unexpectedly: Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by expressing skepticism about COVID-19 shots throughout the pandemic and has zeroed in on potential fatalities following COVID-19 immunization in her brief time at the FDA.

Planned Changes to Pediatric Vaccine Schedule

Public health authorities had intended to unveil major changes to the pediatric immunization program earlier this month, bringing the US with Denmark’s vaccine program, according to reports – a major change that would place the US at odds with much of the global community with little proof for benefit. The announcement has been postponed until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to address the audience at the event. She was just designated temporary leader of the FDA’s CDER, the fifth individual to run the center this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad solidify control at the agency – and it points to a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending some pediatric immunization guidelines in the US to become more in line with Denmark's approach, a country with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

So far statements, she has persisted in emphasizing on immunizations – traditionally the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Doubts Over Expertise

Høeg has no apparent track record in medication creation, approval processes or leadership, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a sizeable institution. She lacks background in industry regulation.”

Former commissioners of the center would “grasp legal statutes and the science of medication creation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who ran the center have had.”

CDER has an vast range of responsibilities at the FDA, the former commissioner stated.

“Everybody just focuses on the novel medication approvals, but the generic drug division clears a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these have to be looked after,” Dr. Woodcock said. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a major management aspect to the role, which supervises over 5,000 staff members. “It’s a huge management job, if you do it right,” Woodcock added.

Agency Reaction and Contentious Initiatives

In response to questions about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson stated that the “inquiries rely on incorrect assumptions”.

“Her resume matches the duties of her job,” the spokesperson said, citing the months Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial one-day medication authorization process that reportedly troubled her preceding directors. “How are these drugs being chosen for this expedited pathway? Who takes the decisions?” Howard asked. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Overall, he remarked, “the FDA appears to be shifting towards more relaxed oversight of pharmaceuticals, aside from vaccines.”

Established History on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if concerning, history, some experts have noted. She released a study using unverified volunteer-provided data to assess the rate of heart inflammation after Covid vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccinations are riskier than they are.

Part of her “desired changes” for the new government encompassed revising rules for new vaccines and discontinuing “unnecessary” vaccines, she stated post-election on a online show. At the FDA, Høeg has according to sources floated the idea of preventing young men from receiving COVID-19 vaccinations.

“She is an all-around true believer who begins with her conclusions and reverse-engineers to retrofit the data in a very disingenuous, dishonest manner,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|